Log In
Print
BCIQ
Print
Print this Print this
 

DLX105

  Manage Alerts
Collapse Summary General Information
Company Delenex Therapeutics AG
DescriptionSmall-size anti-TNF alpha mAb formulated for I.V.
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard Indication Inflammation (unspecified)
Indication DetailsTreat inflammatory diseases
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today